Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.46 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.43 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31413392 | 1.00 | CRBN (0.46) | CRBNIKZF2IKZF1DDB1CSNK1A1 | |
| SCHEMBL27146424 | 0.88 | CRBN (0.48) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL24819319 | 0.88 | IKZF2 (0.44) | CRBNIKZF2IKZF1DDB1CSNK1A1 | |
| SCHEMBL31413474 | 0.85 | CRBN (0.52) | CRBNIKZF2DDB1CSNK1A1 | |
| SCHEMBL32669075 | 0.85 | CRBN (0.52) | CRBNIKZF2DDB1CSNK1A1 | |
| SCHEMBL22345848 | 0.83 | IKZF2 (0.59) | CRBNIKZF2IKZF1DDB1CSNK1A1 | |
| SCHEMBL20231914 | 0.82 | CRBN (0.53) | CRBNIKZF2IKZF1DDB1CSNK1A1 | |
| SCHEMBL29546738 | 0.82 | CRBN (0.53) | CRBNIKZF2IKZF1DDB1CSNK1A1 | |
| SCHEMBL31736558 | 0.80 | CRBN (0.48) | CRBNIKZF2IKZF1DDB1CSNK1A1 | |
| SCHEMBL20046226 | 0.80 | CRBN (0.54) | CRBNIKZF2DDB1CSNK1A1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547658-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | Bristol-Myers Squibb Company (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024006881-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | WEE1, WEE2, PPME1 | CRBN 516/4885IKZF2 2249/4885IKZF1 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.